EIF2AK3 and cancer: Here, our study elucidates that the combination therapy of cisplatin and DHA ensures optimal release of immunostimulatory signals (such as DAMPs) from dying cancer cells ensuring their capacity to stimulate immunosurveillance via the PERK/eIF2α pathway (Fig. 8).